Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 6/20 | 0.55 |
| ▸ | LCK | P06239 | 5/20 | 0.54 |
| ▸ | KDR | P35968 | 4/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.54 |
| ▸ | JAK3 | P52333 | 3/20 | 0.54 |
| ▸ | TEK | Q02763 | 2/20 | 0.54 |
| ▸ | BRAF | P15056 | 5/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.53 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 4/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | BLK | P51451 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4990970 | 0.89 | PTGS1 (0.69) | RAF1LCKKDRMAPK14JAK3 | |
| SCHEMBL4440267 | 0.84 | RAF1 (0.53) | RAF1LCKKDRMAPK14JAK3 | |
| SCHEMBL4436627 | 0.82 | MAPK14 (0.67) | RAF1LCKKDRMAPK14JAK3 | |
| SCHEMBL4421974 | 0.81 | CSF1R (0.52) | LCKKDRMAPK14TEKBRAF | |
| SCHEMBL5498105 | 0.80 | LCK (0.79) | LCKKDRMAPK14JAK3TEK | |
| SCHEMBL4438459 | 0.79 | PIK3CA (0.48) | RAF1LCKKDRMAPK14JAK3 | |
| SCHEMBL4444048 | 0.79 | PTGS1 (0.72) | RAF1LCKKDRMAPK14JAK3 | |
| SCHEMBL17413291 | 0.78 | CSF1R (0.53) | LCKKDRMAPK14TEKBRAF | |
| SCHEMBL678377 | 0.77 | PTGS1 (0.68) | PTGS1CSF1R | |
| SCHEMBL4421970 | 0.77 | CSF1R (0.55) | LCKKDRMAPK14TEKBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841318-B2 | Substituted heterocycles as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-8513270-B2 | Substituted heterocycles as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2121692-B1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2121692-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | INCYTE CORPORATION | 2008-08-07 | — | — | US | disclosed |
| WO-2008079965-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188500-A1 | e.g. N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-3-(trifluoromethyl)benzamide; Janus kinases inhibitor; anticarcinogenic agent; immune-related diseases, skin disorders, myeloid proliferative disorders | JAK3, JAK1, JAK2 | RAF1 466/4885LCK 50/4885KDR 1661/4885 |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | RAF1 247/4885LCK 34/4885KDR 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.